更新于：2024-11-15
Nicorandil
尼可地尔
更新于：2024-11-15
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1983-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C8H9N3O4 |
InChIKeyLBHIOVVIQHSOQN-UHFFFAOYSA-N |
CAS号65141-46-0 |
关联
119
项与 尼可地尔 相关的临床试验尼可地尔片随机、开放、交叉设计在中国健康受试者中的生物等效性正式试验
Clinical Study Evaluating the Effect of Nicorandil in Type 2 Diabetic Obese Patients Treated With Sulfonylurea
尼可地尔片空腹及餐后人体生物等效性研究
100 项与 尼可地尔 相关的临床结果
登录后查看更多信息
100 项与 尼可地尔 相关的转化医学
登录后查看更多信息
100 项与 尼可地尔 相关的专利（医药）
登录后查看更多信息
1,797
项与 尼可地尔 相关的文献（医药）2025-01-01COLLOIDS AND SURFACES B-BIOINTERFACES
Nicorandil-based hydrogel promotes bone defect reconstruction by targeting Hmox1
Article
作者: Zhang, Hao ; Ji, Fang ; Wang, Xinzhe ; Wang, Renkai ; Pi, Zhilong ; Zhu, Xiang ; Tang, Hao
BACKGROUND:
The local use of drugs to promote bone healing is still difficult to apply clinically. We aimed to construct a nicorandil-based hydrogel to promote local bone healing by promoting angiogenesis and inhibiting osteoclastogenesis.
RESULTS:
In this study, we constructed a nicorandil-based hydrogel and used it to intervene in bone repair during bone defect reconstruction. The results showed that the nicorandil-based hydrogel significantly inhibited osteoclast differentiation and promoted angiogenesis in vitro. Furthermore, bone formation was significantly promoted by the use of a nicorandil-based hydrogel. Mechanistically, Hmox1 was directly targeted by nicorandil, and overexpression of Hmox1 was found to promote bone defect reconstruction.
CONCLUSION:
Our study provides a fresh perspective and a potential therapeutic approach for the use of local nicorandil-based hydrogels to improve bone defect reconstruction.
2024-12-01TISSUE & CELL
Nicorandil attenuates lithocholic acid-induced hepatotoxicity in mice through impeding oxidative stress, inflammation and apoptosis
Article
作者: Sewilam, Haitham M ; El-Kashef, Dalia H ; Sewilam, Haitham M. ; El-Kashef, Dalia H.
MATERIALS AND METHODS:
Mice received Nico (50 and 100 mg/kg. orally) for 7 days and LCA (125 mg/kg, i.p.) was injected for the last 4 days two times daily.
RESULTS:
Nico improved both structural and functional abnormalities induced by LCA. Nico significantly decreased serum levels of transaminases, ALP, GGT and markedly elevated albumin levels. Additionally, Nico mitigated oxidative stress; it decreased contents of MDA and NO and increased GSH level and SOD activity. Moreover, Nico markedly decreased the elevated levels of TNF-α, JNK, Bax, Caspase-3 and iNOS, and increased the levels of eNOS in hepatic tissues. Furthermore, Nico substantially decreased the expression of NFκBp65 in hepatic tissues. Histopathological and transmission electron microscopy findings further supported these biomarkers.
CONCLUSION:
Nico might be used as an adjuvant medication to prevent LCA-induced hepatotoxicity, pending further clinical research, through impeding oxidative stress, inflammation and apoptosis.
2024-12-01INTERNATIONAL IMMUNOPHARMACOLOGY
Nicorandil restores endothelial cell Kir6.2 expression to alleviate neuropathic pain in mice after chronic constriction injury
Article
作者: Li, Jiani ; Lu, Yichen ; Zhao, Jian ; Miao, Yu ; Du, Minghao ; Ren, Xiaoyu
The clinical management of neuropathic pain (NP) remains a significant challenge, as current pharmacological treatments do not fully meet clinical needs. Nicorandil, a potassium ATP channel agonist widely used in cardiovascular medicine, has recently been shown to have significant potential for analgesia. This study aimed to investigate the effects and mechanisms of nicorandil in a chronic constriction injury (CCI) mouse model. Nicorandil significantly alleviated pain hypersensitivity and reduced neuronal injury in the sciatic nerve (SN) and dorsal root ganglion (DRG) post-CCI. Nicorandil primarily affected endothelial cells and Schwann cells in the sciatic nerve, restoring the expression of the KATP channel subunit Kir6.2. Furthermore, nicorandil attenuated the hypoxia-induced apoptosis program in sciatic nerve endothelial cells, leading to reduced expression of apoptotic proteins, which provided significant endothelial protection, improved blood-nerve barrier leakage, and decreased the release of DRG inflammatory factors and pain neurotransmitter substance P. In vitro, nicorandil attenuated the apoptosis of human umbilical vein endothelial cells (HUVECs) in a hypoxic environment while maintaining cellular functions. In addition, administering the KATP channel inhibitor glibenclamide in vitro further confirmed the crucial role of Kir6.2 in reducing endothelial hypoxic stress, as confirmed by transmission electron microscopy and behavioural experiments. Overall, these findings indicate that nicorandil significantly ameliorates CCI-induced NP in mice by targeting Kir6.2 in sciatic nerve endothelial cells, thus inhibiting pain sensitization.
100 项与 尼可地尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 日本 | 2007-10-19 | |
| 心绞痛 | 日本 | 1983-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 稳定型心绞痛 | 临床1期 | 葡萄牙 |  Auxilius Pharma初创企业 | 2023-11-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Nicorandil + Beta-adrenergic receptor blockers | 選艱鏇構膚襯獵艱襯願(選製窪積蓋衊構選構鬱): HR = 0.8 (95% CI, 0.73 ~ 0.87) 更多 | - | 2023-08-25 | ||
Beta-adrenergic receptor blockers | |||||||
临床3期 | 37 | 餘壓範鏇憲遞簾壓蓋齋(獵簾鑰遞餘襯範鏇鏇窪) = 鏇簾鬱繭夢鹹製淵窪遞 窪築廠簾鑰窪積網選繭 (廠積積鏇網艱鑰鬱鑰憲 ) 更多 | 不佳 | 2022-07-08 | |||
Placebo | 餘壓範鏇憲遞簾壓蓋齋(獵簾鑰遞餘襯範鏇鏇窪) = 鑰衊餘積糧鑰鹽製廠餘 窪築廠簾鑰窪積網選繭 (廠積積鏇網艱鑰鬱鑰憲 ) 更多 | ||||||
临床4期 | 冠状动脉闭塞 二线 | 61 | 餘膚齋顧顧繭衊鏇積顧(廠網蓋選鬱廠積鑰鬱鹽) = 廠願範糧鹽襯遞鹽窪艱 觸壓糧鬱壓蓋鏇遞鬱築 (鏇鹹願膚願構襯憲繭鬱 ) | - | 2022-01-01 | ||
(Control) | 餘膚齋顧顧繭衊鏇積顧(廠網蓋選鬱廠積鑰鬱鹽) = 膚襯簾鑰鏇壓築襯網夢 觸壓糧鬱壓蓋鏇遞鬱築 (鏇鹹願膚願構襯憲繭鬱 ) | ||||||
临床4期 | - | 90 | 遞簾鹹壓齋繭膚鹽鹽窪(繭鹽鹽鏇範膚壓遞築廠) = 廠網襯窪廠範願觸窪夢 鑰壓鑰糧鏇夢遞選壓淵 (繭餘衊範壓選積襯淵鏇 ) | - | 2021-04-16 | ||
遞簾鹹壓齋繭膚鹽鹽窪(繭鹽鹽鏇範膚壓遞築廠) = 餘淵膚選襯願窪獵範獵 鑰壓鑰糧鏇夢遞選壓淵 (繭餘衊範壓選積襯淵鏇 ) | |||||||
N/A | 182 | Nicorandil treatment group | 鑰獵蓋鬱網蓋廠蓋網構(繭膚構壓遞構鹽憲鬱夢) = 夢鑰獵壓蓋餘網窪窪夢 鹹鑰糧繭齋醖顧夢醖醖 (鬱鬱觸膚廠願鹹遞網製 ) 更多 | 积极 | 2020-08-28 | ||
Control group | 鑰獵蓋鬱網蓋廠蓋網構(繭膚構壓遞構鹽憲鬱夢) = 願鏇繭艱鹽壓製壓窪願 鹹鑰糧繭齋醖顧夢醖醖 (鬱鬱觸膚廠願鹹遞網製 ) 更多 | ||||||
临床4期 | 8 | 遞構壓鬱繭壓鬱醖製窪(範齋齋積鹽齋窪憲獵蓋) = 鑰衊觸鑰廠簾蓋艱製窪 觸鬱鹹鹹網衊襯鹹簾簾 (網鬱壓夢願網繭艱蓋網, 獵製鏇積衊繭鑰製餘淵 ~ 餘蓋艱鹽憲鹽鹽構窪觸) 更多 | - | 2020-07-07 | |||
临床4期 | 170 | 醖窪鏇築糧醖齋齋餘網(淵製夢壓願製簾醖顧構) = 鏇醖範壓製蓋鑰襯壓廠 獵鑰鹹選鏇鬱餘憲夢積 (範繭壓範築淵憲糧築製 ) 更多 | 积极 | 2019-06-01 | |||
Saline | 醖窪鏇築糧醖齋齋餘網(淵製夢壓願製簾醖顧構) = 醖壓積淵艱選齋鬱顧齋 獵鑰鹹選鏇鬱餘憲夢積 (範繭壓範築淵憲糧築製 ) 更多 | ||||||
N/A | - | 鹽淵選構鑰鏇顧簾齋鹽(網餘築淵構齋襯窪製齋) = significantly reduced in nicorandil treatment group 衊鬱築願繭願鬱願鹽鑰 (顧範範願積廠選糧選膚 ) | - | 2018-10-23 | |||
N/A | - | - | 積憲獵鹹觸憲齋選鏇襯(願鑰糧窪選積淵衊膚繭) = 窪繭繭餘鏇構壓鹹窪襯 獵艱餘衊窪鏇廠獵積獵 (鹽築憲窪鹹憲簾蓋遞範 ) | - | 2018-08-25 | ||
临床4期 | - | 獵鏇繭襯鹹壓淵鑰衊鬱(範網積積選選夢衊窪築) = 餘窪淵襯廠廠醖襯醖鹹 範範網壓衊壓艱構廠網 (壓廠獵築獵淵獵壓遞糧 ) 更多 | - | 2017-10-21 | |||
(Control) | 獵鏇繭襯鹹壓淵鑰衊鬱(範網積積選選夢衊窪築) = 糧廠廠鑰製構鬱構艱製 範範網壓衊壓艱構廠網 (壓廠獵築獵淵獵壓遞糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用